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Abstract
The results of several lipid-lowering randomized trials have been released during the past years and have confirmed the 
lipid hypothesis. Reduction of cholesterol by potent drugs in clinically symptomatic or asymptomatic patients with 
above-average cholesterol levels will substantially reduce the risk of coronary events. The present article gives a review of 
potent low-density lipoprotein cholesterol-lowering treatments and discusses developments in hypolipidaemic therapy in 
relation to recent primary and secondary prevention studies. In addition, possible mechanisms of cholesterol lowering in 
retardation of the atherosclerotic process are summarised. © 1997 Elsevier Science B.V.
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1. Introduction
Cardiovascular diseases are the major cause of 
death in the Western societies. In the Netherlands 
40% of all deaths in 1993 were caused by cardio­
vascular diseases, of which 40% were ischaemic 
heart disease and 23% cerebrovascular disease. The 
ability to prevent the development of atherosclerosis 
or, alternatively, to reduce the severity of established 
atherosclerotic plaques, often referred to as regres­
sion, has major implications for health care.
The validity of the lipid hypothesis has been 
debated for more than 40 years. The relation between
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total cholesterol and low-density lipoprotein (LDL) 
cholesterol levels and the incidence of coronary artery 
disease (CAD) and peripheral vascular disease (PVD) 
is now well established [1-3]. Epidemiological stud­
ies have shown parallel, age-related trends of athero­
sclerotic lesions in the abdominal aorta, carotid, and 
coronary arteries [4,5]. Since the beginning of the 
1980s, many primary and secondary prevention tri­
als, predominantly conducted in men with hyper- 
cholesterolaemia, have shown that lipid-lowering 
regimens result in reduction of angiographic lesions 
and are associated with a decreased incidence of 
atherosclerotic events [6-38]. Most of these tiñáis 
have shown slowing or arrest of progression of 
coronary atherosclerosis. Reports concerning femoral 
atherosclerosis are more scarce [7,14-16,21,24,25], 
In several recent clinical trials on plasma lipid regu­
lation, measurements of carotid artery intima-media
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thickness (IMT) have been included, because coro­
nary and carotid atherosclerosis share coronary events 
as their major cause of morbidity and mortality 
[38-41]. Indeed, most of these studies have also 
shown a slowing of progression of IMT during 
lipid-lowering treatment.
The common denominator of most of these trials 
is reduction of LDL cholesterol [42]. However, the 
results of the recently published Bezafibrate Coro­
nary Atherosclerosis Intervention Trial (BECAIT) 
may also indicate a role for lowering serum triglyc­
erides and raising high-density lipoprotein (HDL) 
cholesterol in reversing the progression of athero­
sclerosis [35]. With the introduction of more potent 
cholesterol-lowering agents, the 3-hydroxy-3~ 
me thy 1-glut aryl coenzyme A (HMG-CoA) reductase 
inhibitors, the effects of lipid lowering on coronary 
and total mortality have been solidly confirmed, 
changing the lipid hypothesis into evidence [43]. In 
this article the background of LDL-cholesterol- 
lowering treatment will be discussed in relation to an 
update of the insights provided by atherosclerosis 
regression studies.
2* LDL-cholesterol-lowering treatments
We will focus on treatment with HMG-CoA re­
ductase inhibitors because these drugs have made a 
major impact on the therapy of hypercholesterol- 
aemic patients, in terms of both efficacy and tolera- 
bility. In addition, the value of treatment with LDL- 
apheresis will be discussed for more aggressive sec­
ondary prevention in drug-refractory cases.
2.L HMG-CoA reductase inhibitors
HMG-CoA reductase is an enzyme that catalyses 
the rate-limiting step in cholesterol biosynthesis [44], 
HMG-CoA reductase inhibitors reduce serum choles­
terol levels by inhibiting the endogenous synthesis of 
cholesterol, thereby upregulating LDL receptors, es­
pecially in the liver [45,46], This leads to increased 
removal from plasma of LDL as well as the precur­
sors of LDL, intermediate density lipoproteins (IDL). 
This dual mechanism of decreased production and 
increased removal of LDL causes large reductions in 
serum cholesterol concentrations. Over the past few
years numerous studies have shown the efficacy and 
safety of 4 HMG-CoA reductase inhibitors currently 
available: lovastatin, simvastatin, pravastatin, and 
fluvastatin, A reduction of total cholesterol ranging 
from 23-45% (mean 30%) can be achieved, due to a 
26-42% (mean 35%) reduction of LDL-cholesterol. 
This effect is accompanied by a 11-32% (mean 
20%) decrease in serum triglycerides and a 8-13% 
(mean 8%) increase of HDL-cholesterol [47,48]. 
Some reports have shown an increase in 
lipoprotein(a) [Lp(a)] levels during treatment with 
the statins, ranging from 8-12% [30,37,49], On a 
milligram basis simvastatin is twice as potent as 
pravastatin and lovastatin, and 4 times as potent as 
fluvastatin [50,51]. The not yet approved drug, ator- 
vastatin, has been reported to decrease LDL- 
cholesterol even more by up to 60% and reduce 
triglyceride levels by up to 40% [52,53], probably 
due to its long plasma half-life.
In general, HMG-CoA reductase inhibitors are 
well tolerated and side-effects are neither serious nor 
frequent [47]. Apart from increases in liver enzyme 
levels greater than 3-fold the upper normal limit, 
which occur in approximately 1% of statin-treated 
patients, the myopathy syndrome (elevation of crea­
tine kinase activity above 10-fold the upper normal 
limit plus muscle pain or weakness) is the only 
side-effect worth mentioning. The incidence of myo­
pathy during monotherapy with statins is approxi­
mately 1 in 1000, although the combination with 
fibrates, cyclosporin, nicotinic acid and erythromycin 
might amplify this risk [54],
In animal studies, treatment with HMG-CoA re­
ductase inhibitors has been shown to retard the de­
velopment of atherosclerosis [55,56]. Moreover, in­
tensive lipid lowering using HMG-CoA reductase 
inhibitors is the most effective in terms of inducing 
plaque regression and reducing the number of clini­
cal events in men with established CAD and PVD 
[18,19,25,28,30-41]. Recently, a meta-analysis that 
pooled data from four studies treating men and 
women with 10-40 mg per day pravastatin for 2-3 
years showed that a decrease in LDL-cholesterol of 
28% from baseline was associated with a 62% reduc­
tion in the combined incidence of non-fatal and fatal 
myocardial infarction [57]. More aggressive lipid 
lowering may even improve these benefits [58]. 
Therefore, if treatment goals in lowering LDL-
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cholesterol are not reached, combination therapy with 
a reductase inhibitor and a bile-acid sequestrant 
should be considered. Since many patients with CAD 
show a combined elevation of total cholesterol and 
triglycerides, due to increases in the circulating 
masses of both LDL and very-low-density lipopro­
teins (VLDL), combination therapy of a reductase 
inhibitor and a fibric acid should be considered in 
these cases [59]. However, adverse reports linking 
myopathy to the use of this drug combination call for 
caution in the use of this regimen [60].
2.2. LDL-apheresis
In addition to drug treatment, alternative ap­
proaches to cholesterol-lowering have been per­
formed by portocaval shunting, liver transplantation 
and plasmapheresis [61-63]. The latter has been 
shown to reduce mortality of CAD [64]. New tech­
niques have been developed to replace plasmaphere­
sis, which selectively remove apolipoprotein-B-
►
containing lipoproteins from plasma [65-69]. The 
performance of regular LDL-apheresis permits the 
achievement of lower levels of LDL-cholesterol, 
which are usually not possible to attain with drug 
therapy alone [70-73]. Adverse events from LDL- 
apheresis are infrequent and similar to any extracor- 
poreal treatment. They mainly include hypotension 
and chills, which have been reported with frequen­
cies of 0.2-1.1% and 0.3-6.0%, respectively [70,73]. 
LDL-apheresis has been shown to change peripheral 
and cerebral haemodynamics favourably by short­
term improvements in the rheological properties of 
whole blood and probably also by restoring endothe­
lium-dependent vasodilation [74,75]. The application 
of this method may offer opportunities in the preven­
tion of progression of atherosclerosis as has been 
shown in selected patients with a primary hyperlipi- 
daemia and established CAD or PVD refractory to 
drug treatment [24,37,38,76-81].
3. Clinical trials
In 1994, convincing evidence for the value of 
lipid-lowering therapy in reducing clinical CAD 
events was published in a meta-analysis of 28 ran­
domized controlled, primary and secondary preven­
tion trials by Law et al. [82], The analysis indicated 
that in men 55-64 years of age, a 10% decrease in 
total cholesterol produced a 7% reduction in is­
chaemic events during the first 2 years of the trial, a 
22% reduction during years 2-5, and a 25% reduc­
tion after 5 years of the trial. These findings are 
consistent with a lag period between the initiation of 
lipid-lowering therapy and a reduction in clinical 
events.
3.1. Primary prevention trials
The early primary prevention trials were too small 
to demonstrate significant changes in mortality [82]. 
The Lipid Research Clinics Coronary Primary Pre­
vention Trial (LRC-CPPT), a 7-year placebo-con- 
trolled study in 3806 men with elevated cholesterol 
[8,9], and the 5-year Helsinki Heart Study (HHS), in 
4081 men with elevated LDL and/or very-low-den- 
sity lipoprotein (VLDL) cholesterol [12], both showed 
a reduction in coronary events after long-term treat­
ment with cholestyramine and gemfibrozil, respec­
tively (Table 1). The investigators of the LRC-CPPT 
showed that each 1% reduction in serum cholesterol 
would result in an approximately 2% reduction in the 
risk of CAD [9]. After the disappointing results on 
mortality of the very large World Health Organiza­
tion Clofibrate Trial [6], the LRC-CPPT and the 
HHS actually initiated the wide acceptance of the 
favourable effects of lipid-lowering treatment on car­
diac mortality or CAD incidence, although much 
debate was raised by the increase in non-cardiac 
mortality (Table 1). This excess of deaths in the 
intervention groups has been explained by the use of 
fibrates, but also by an overestimation due to inten­
tion-to-treat analyses [84,85]. To overcome some of 
the limitations of the LRC-CPPT, in which the de­
crease in cholesterol was less than expected due to 
poor compliance to the study drug, or of the HHS, 
which used an agent less effective in lowering LDL- 
cholesterol, the West of Scotland Coronary Preven­
tion Study (WOSCOPS) was designed using one of 
the HMG-CoA reductase inhibitors (Table 1) [34]. In 
this double-blind, randomized, placebo-controlled 
trial 6595 Scottish men between 45 and 64 years of 
age with a mean LDL-cholesterol of 5.0 mmol/1 
were treated with 40 mg per day pravastatin or 
placebo for a mean of 4.9 years. LDL-cholesterol























LA-VA [83] 846 7 -1 3  * -3 2 -2 3 n.c.
WHO-clofibrate [6] 10627 5.3 - 9  * -2 6  * -2 0  * + 36 *
LRC-CPPT [8] 3806 7.4 - 9  * -1 9 -1 9  * + 33
HHS [12] 4081 5 -1 0  * -3 6 -3 4  * + 25
WOSCOPS [34] 6595 4.9 — 20* -3 1  * —*31 -11
Data represent percent changes in the intervention group versus the control group. MI = myocardial infarction; CAD — coronary artery 
disease; n.c. = not changed.
Statistically significant change.
was lowered on average by 26% and the major 
end-point, death from CAD or non-fatal myocardial 
infarction, showed a significant reduction of 31%, 
whereas overall mortality was reduced by 22% with­
out excess of non-cardiovascular deaths. This study 
unequivocally showed that primary prevention with a 
well-tolerated and potent drug, in a population at 
increased risk for CAD and no history of myocardial 
infarction, is effective and may also have a major 
impact for health care costs. The clinical benefits of 
lipid-regulating therapy in primary prevention trials 
preceding the WOSCOPS have been less dramatic 
and a matter of constant debate. However, hyper- 
cholesterolaemic individuals without established 
CAD represent an important population who will 
eventually die or become disabled by CAD events. 
Several studies are now in progress, which may 
provide more information about the benefits and 
risks of several treatment modalities in the primary 
prevention of CAD [86].
3.2. Secondary prevention trials
The Scandinavian Simvastatin Survival Study (4S) 
and the Cholesterol and Recurrent Events (CARE) 
trial, both double-blind, randomized, placebo-con­
trolled studies, provided definitive evidence of the 
benefit of lowering LDL-cholesterol in patients with 
established CAD [31,36]. In 4S, 4444 men and 
women with serum total cholesterol levels between
5.5 and 8.0 mmol/1 were allocated to 20-40 mg per 
day simvastatin or placebo. After a median treatment 
period of 5.4 years, LDL-cholesterol was lowered on 
average by 35%, and total mortality was reduced by
30% because of a CAD mortality rate reduction of 
42% in the simvastatin-treated patients. In the 5-year 
CARE study, 4159 men and women with a plasma 
total cholesterol level of less than 6.2 mmol/1 and 
an LDL-cholesterol of 3.0-4.5 mmol/1 were as­
signed to 40 mg per day pravastatin or placebo, 
LDL-cholesterol was lowered by 32% and main­
tained mean levels of 2.5 mmol/1 throughout the 
follow-up. Fatal or non-fatal coronary events were 
significantly reduced by 24% due to an absolute risk 
reduction from 13.2 to 10.2% in the placebo- and 
pravastatin-treated group, respectively. Interestingly, 
no significant differences in non-cardiovascular mor­
tality were observed in either study, and moreover, 
women seemed to benefit more from treatment than 
men in CARE.
Evidently, lipid lowering in a population with 
established CAD is more effective in reducing coro­
nary and total mortality. However, since the separa­
tion of cholesterol-lowering trials into those studying 
primary and those studying secondary prevention has 
little foundation in coronary pathology, WOSCOPS, 
4S, and the CARE study indicate that more aggres­
sive lipid lowering further reduces the progression of 
CAD. Indeed, renewed meta-analysis of randomized 
cholesterol-lowering trials has shown a regression 
line between CAD and total mortality versus the 
percent of cholesterol reduction, indicating that far­
ther lowering of total cholesterol concentrations is 
associated with a decreased mortality [84]. As has 
been indicated by the meta-analysis of Law et al. 
[82], the greatest changes in atherosclerosis may be 
found after more than 2 years of intervention. More­
over, a recent analysis of 11 angiographic coronary
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atherosclerosis regression studies showed that reduc­
tion of LDL-cholesterol by 44% for the duration of
2.6 years in patients with CAD should completely 
arrest the progression of the disease [87],
4. Degree of cholesterol lowering
Current international guidelines for the secondary 
prevention of CAD in Europe and the USA stipulate 
that LDL-cholesterol levels should be reduced to 
3-3.5 and to 2.6 mmol/1 or below, respectively 
[88,89]. However, the recently published subgroup 
analysis of 4S showed that the percentage reduction 
in LDL-cholesterol (32-37%) and decrease in rela­
tive risk of CAD in patients on simvastatin (32-36%) 
was comparable and constant across all quartiies of 
baseline LDL-cholesterol, which ranged from below 
4.39 mmol/1 in the lowest quartile to more than 5*39 
mmol/1 in the highest quartile [90]. This indicates 
that, at least in subjects with baseline total choles­
terol levels between 5.5 and 8.0 mmol/1, the per­
centage reduction in LDL-cholesterol rather than its 
absolute level on treatment may determine clinical 
benefit, since subjects in 4S with LDL-cholesterol 
levels well above the recommended value showed 
the same reduction in CAD risk as those below these 
levels. Indeed, it has been shown in a subgroup of 11 
coronary atherosclerosis regression studies that the 
percent change in diameter stenosis of coronary ar­
teries correlated with the percent change in LDL- 
cholesterol during the study and not with on-trial 
levels [87]. In the CARE trial, however, patients in 
the lowest tertile with baseline LDL-cholesterol lev­
els below 3.2 mmol/1 did not benefit from pravas­
tatin treatment with regard to reduction in coronary 
events [36]. These results are consistent with epi­
demiological studies that show a stronger relation 
between LDL-cholesterol levels and coronary events 
at hyperchólesterolaemic, as compared with average, 
levels [91], as well as some angiographic studies 
which showed that improvement in coronary artery 
stenosis in patients receiving lipid-lowering therapy 
is proportional to the baseline LDL-cholesterol level 
[26,92]. Although these data need confirmation, they 
suggest limits to the clinically important influence of 
the LDL-cholesterol level on CAD. Consequently,
the issue of cholesterol-lowering to recommended, 
fixed target values versus guidelines in percent re­
duction of baseline cholesterol levels is not yet com­
pletely solved.
5. Mechanisms of cholesterol lowering in retarda­
tion of atherosclerosis
Several mechanisms have been suggested by 
which lowering of LDL-cholesterol may confer clini­
cal benefit, including stabilization of rupture-prone 
atherosclerotic lesions, decreased LDL-oxidizability, 
improvement of vascular endothelial function, and 
reduction of an inflammatory or immunological re­
sponse associated with atherosclerosis [93].
5.L Plaque stabilization
Statins may have stabilizing and protective effects 
on atherosclerotic lesions, by making them less vul­
nerable to fissure and rupture. The culprit lesion 
causing thrombosis of the coronary arteries is thought 
to be 30-70% stenoses in the majority of cases. 
These lesions, characterised by a lipid-rich core, a 
thin fibrous caps, few smooth muscle cells and fi­
broblasts, and a large number of foam cells particu­
larly at the shoulders of the caps, are prone to 
rupture and lead to thrombotic occlusions and conse­
quent clinical events [94,95]. Moreover, enhanced 
vasoconstriction potentially promotes plaque Assur­
ing and ulceration, which may lead to thrombosis 
[96,97]. Evidently, there seems to be a dissociation 
between the results of angiographic studies and clini­
cal outcome: lipid-lowering therapy has been shown 
to reduce the incidence of cardiovascular events with 
only small changes in coronary anatomy [98,99]. 
Therefore, it is most likely that treatment of hyper- 
cholesterolaemia depletes the lipid core of early 
atheromatous plaques, and consequently stabilizes 
these lipid-rich lesions and prevents further compli­
cations such as intramural haemorrhage and intralu­
minal thrombosis, an assumption that has been 
demonstrated in the Canadian Coronary Atheroscle­
rosis Intervention Trial (CCAIT) and the Stanford 
Coronary Risk Intervention Project (SCRIP) [28,100].
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5.2. LDL-oxidizability
Oxidative modification of LDL plays a key event 
in the development of atherosclerosis. It has been 
shown that LDL must undergo oxidative modifica­
tion before it can be taken up by macrophages 
[93,101]. Oxidative modification of LDL, maybe me­
diated by cell-surface receptors [ 102], converts it to a 
form recognised by the macrophage scavenger recep­
tor [103], leading to its unlimited uptake and the 
formation of foam cells, an early hallmark of athero­
sclerotic plaques. In addition to promoting excess 
lipid accumulation, oxidised LDL may facilitate the 
progression of atherosclerotic lesion by disrupting 
normal endothelial cell function [104]. The finding of 
oxidised LDL and lipid peroxides in areas of athero­
sclerotic plaques and the observation that antioxidant 
treatment with probucol and vitamin E slows the 
progression of atherosclerosis in the animal model 
strongly support the role of LDL modification in 
atherogenesis [105-109]. Recently the results of a 
randomized, controlled trial of vitamin E in normoc- 
holesterolaemic subjects with CAD, the Cambridge 
Heart Antioxidant Study (CHAOS), were published 
[110]. The authors showed that treatment with 400™ 
800 IU of a-tocopherol per day significantly reduced 
the number of non-fatal coronary events after 1 year 
of treatment, although total mortality was increased 
in this group. It is too early to advocate secondary 
prevention with pharmacological doses of vitamin E, 
since in the animal model a decrease in oxidative 
susceptibility alone has been shown not to be suffi­
cient to attenuate atherogenesis when cholesterol lev­
els remain markedly elevated [111,112], Recent evi­
dence indicates that oxidized LDL inhibits endothe­
lium-dependent arterial relaxation by diminishing the 
release of vasoactive compounds such as endothe­
lium-derived relaxing factor [113].
5.3. Endothelial cell dysfunction
Lowering of LDL-cholesterol is also of impor­
tance for the restoration of the hypercholesterol- 
aemia-induced endothelial dysfunction [114]. The 
normal endothelium participates in the regulation of 
the vascular tone by releasing substances with both 
anti-aggregating and vasodilating properties, such as 
prostacyclin and endothelium-derived relaxing factor
(EDRF), identified as nitric oxide (NO), and also 
substances with contracting properties, such as en- 
dothelin [115,116], Early in the process of develop­
ment of atherosclerosis increased reactions to con­
tractile agonists and attenuated vasodilating re­
sponses have been observed [117]. It has been shown 
in animal models that the release of protective, anti- 
aggregating and vasodilating substances is dimin­
ished due to atherosclerosis of the vessels and also as 
a consequence of hypercholesterolaemia per se 
[118-122]. In humans, coronary atherosclerosis and 
hypercholesterolaemia have also been associated with 
dysfunction of endothelium-mediated vasomotion, 
which impairs coronary or myocardial blood flow 
and forearm blood flow [123-126]. Lipid-lowering 
therapy has shown to improve the endothelium medi­
ated vasomotion after relative short periods of time 
[127-129]. For example, Egashira et al. [127] 
demonstrated a significant improvement in coronary 
blood flow in response to acetylcholine infusion in 
patients with hypercholesterolaemia and pravastatin 
therapy. Anderson et al. [130] showed recently that 
the addition of antioxidant therapy with probucol to 
cholesterol-lowering treatment with lovastatin im­
proved acetylcholine-induced, endothelium-depen­
dent vasodilation significantly more than cholesterol 
lowering alone. Moreover, in this process of reversal 
it has been found that functional improvements of 
the coronary circulation precede the structural, 
anatomical improvements [131].
5.4. Reduction of inflammatory or immunological 
response
The data are consistent with a pathogenetic role of 
endothelial-cell injury, impaired fibrinolysis, and in­
flammatory activities in the progression of CAD 
[132]. The initial inciting event in atherosclerosis is 
intimal lipid deposition, which is followed by re­
cruitment of inflammatory cells (monocytes and T- 
lymphocytes) into the intima, smooth muscle cell 
accumulation, and elaboration of collagen and matrix 
proteins by smooth muscle cells. These processes 
have been shown to be mediated by minimally modi­
fied LDL, and induces the expression of and inter­
play between adhesion molecules (selectins, ICAM-1, 
and VCAM-1), monocyte chemotactic proteins (e.g., 
MCP-1), growth factors (e.g., PDGF), and cytokines
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(IL-l, IL-4, IL-6 , TNFot, and INF7 ) [103,133,134],
It has been shown that systemic administration of 
oxidised LDL stimulates leucocyte adhesion and 
platelet aggregation to the vascular endothelium 
[135], In both man and rabbits, autoantibodies are 
found which recognize and selectively bind oxidised 
LDL [105]. Moreover, the titre of autoantibodies 
binding malondialdehyde-LDL was found to be an 
independent predictor of the progression of carotid 
atherosclerosis in man [136]. The proliferation of 
smooth muscle cells is promoted by a number of 
growth factors, including IL-l (3 and IL-l a , which 
are secreted by activated monocytes, macrophages, 
and endothelial cells [137]. Oxidised LDL has been 
shown to activate T-cells, which modulate the re­
lease of IL-1(B and TNFa [138], whereas IL-4 has 
been found to induce 15-lipoxygenase activity of 
human monocytes, initiating lipid peroxidation [134],
6. Conclusion
The benefits of reducing cholesterol are now es­
tablished beyond any reasonable doubt. The data 
indicate that several potential atherosclerosis reversal 
mechanisms exist, of which the reduction of the 
number of LDL particles is a central one. Treatment 
should be aimed primarily at reducing LDL- 
cholesterol, and secondarily at reducing triglycerides 
and raising HDL [139]. However, the prevention of 
CAD is too large an issue to be accomplished by 
drugs alone. A population-based strategy to decrease 
the incidence of CAD further must continue to focus 
on reducing the dietary content of saturated fat and 
cholesterol [140].
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